Sfakianaki, M.; Papadaki, C.; Tzardi, M.; Trypaki, M.; Manolakou, S.; Messaritakis, I.; Saridaki, Z.; Athanasakis, E.; Mavroudis, D.; Tsiaoussis, J.;
et al. PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer. Cancers 2020, 12, 2058.
https://doi.org/10.3390/cancers12082058
AMA Style
Sfakianaki M, Papadaki C, Tzardi M, Trypaki M, Manolakou S, Messaritakis I, Saridaki Z, Athanasakis E, Mavroudis D, Tsiaoussis J,
et al. PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer. Cancers. 2020; 12(8):2058.
https://doi.org/10.3390/cancers12082058
Chicago/Turabian Style
Sfakianaki, Maria, Chara Papadaki, Maria Tzardi, Maria Trypaki, Stavroula Manolakou, Ippokratis Messaritakis, Zenia Saridaki, Elias Athanasakis, Dimitrios Mavroudis, John Tsiaoussis,
and et al. 2020. "PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer" Cancers 12, no. 8: 2058.
https://doi.org/10.3390/cancers12082058
APA Style
Sfakianaki, M., Papadaki, C., Tzardi, M., Trypaki, M., Manolakou, S., Messaritakis, I., Saridaki, Z., Athanasakis, E., Mavroudis, D., Tsiaoussis, J., Gouvas, N., & Souglakos, J.
(2020). PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer. Cancers, 12(8), 2058.
https://doi.org/10.3390/cancers12082058
